elenco-ab-generico
ABSTRACT LIST
- Serum neurofilament light chain in relation to autonomic neuropathy in hereditary transthyretin amyloidosis
- Therapeutic Challenges in ATTRv Neuropathy: The Need for Early Prediction of Treatment Failure
- Silence Project: Use of transthyretin silencers in real clinical practice in variant transthyretin amyloidosis (ATTRv) in Spain.
- Deep insight in diflunisal treatment in ATTR-amyloidosis with polyneuropathy.
- Unraveling the Genetic Landscape of Transthyretin Amyloidosis in the Balearic Islands: Evidence for a Unique Founder Effect
- Clinical and Neurophysiological Correlates of Neuropathic Pain in ATTRv amyloidosis with Neuropathy
- Neurophysiological Insights in ATTR Hereditary Amyloidosis with Neuropathy: Early Markers
- MaesTTRo: Initial experience from a prospective, non-interventional, multi-country study of patients with amyloid transthyretin amyloidosis
- Early symptoms and medical history of patients with transthyretin amyloidosis cardiomyopathy: results from the multi-country OverTTuRe study
- Estimating meaningful differences in measures of autonomic symptom impairment and overall disability in patients with hereditary transthyretin amyloidosis with polyneuropathy
- Eplontersen slows disability progression and deterioration of gait speed in patients with hereditary transthyretin amyloidosis with polyneuropathy
- Real-world post-diagnosis treatment patterns and outcomes in patients with ATTR amyloidosis: Results from the multi-country OverTTuRe study
- Efficacy and safety of nexiguran ziclumeran, an investigational CRISPR/Cas9 gene editing treatment: 24-month follow-up from a phase 1 study in patients with hereditary ATTR with polyneuropathy
- Characteristics, treatment patterns, and outcomes of patients with hereditary transthyretin amyloidosis: an observational, retrospective study in China (OverTTuRe China)
- HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
- Clinical presentation and treatment landscape of patients with transthyretin amyloidosis with cardiomyopathy: A real-world study in five European countries and Japan
- Design and rationale of a phase 3 study to evaluate the efficacy and safety of nucresiran (ALN-TTRsc04) in patients with transthyretin amyloidosis with cardiomyopathy
- Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRibute-CM trial
- Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy
- ACO-REAL – a non-interventional study providing insights into the use of acoramidis in people with transthyretin amyloid cardiomyopathy in routine clinical practice
- Hereditary transthyretin amyloidosis: Inheritance pattern and disease phenotype within the Swedish population
- Incidence, patient characteristics and clinical outcomes of amyloid polyneuropathy: an observational study in England using electronic health records
- Long-term efficacy and safety of eplontersen in patients with hereditary transthyretin amyloidosis with polyneuropathy: initial report from the open-label extension of the NEURO-TTRansform study
- Radiographic spinal changes in amyloidosis-positive patients: comparative MRI and CT analysis of operated and non-operated levels
- Clinician Preferences for Transthyretin Amyloidosis Treatment: Results from a Discrete-Choice Experiment
- Fast-tracking cardiac amyloidosis detection from 12-lead ECG: validating the deep learning model Willem AI platform
- Evolving trends in hereditary ATTR amyloidosis: an analysis of the retrospective cohort CARDINAL study in Portugal
- In participants treated with acoramidis, addition of concomitant tafamidis did not further increase serum TTR levels
- Validation of an algorithm to identify patients with amyloid transthyretin cardiomyopathy (ATTR-CM) in linked real world data from the Netherlands – the ValidATTR study
- Risk of newly occurring polyneuropathy in patients diagnosed with amyloid transthyretin cardiomyopathy
- A real-world study of health-related quality of life among patients with transthyretin amyloidosis with polyneuropathy
- Cardiac phenotype in hereditary transthyretin amyloidosis: Correlation between fibril types and 99mTc-DPD uptake
- Early Six-Month Quantitative Assessment Predicts Neurological Conversion Risk in Asymptomatic ATTRv Carriers
- Acoramidis-mediated early increase in serum transthyretin level reduces cardiovascular-related hospitalizations and mortality: insights from the ATTRibute-CM study
- TRANSTHYRETIN AMYLOID CARDIOMYOPATHY IN A SOUTHEAST ASIAN POPULATION
- Identifying unmet needs in the holistic clinical management of patients with transthyretin amyloidosis with cardiomyopathy
- An Interventional Pilot Study on the Feasibility and Acceptance of a Psychological Support Program for Patients, Caregivers, and Presymptomatic Carriers in Hereditary Transthyretin Amyloidosis
- Experience with Vutrisiran in ATTRv neuropathy in a single non endemic center
- Temporal Evolution of Transthyretin Cardiac Amyloidosis Phenotypes on Cardiac Magnetic Resonance
- Lower mitochondrial DNA copy number in Swedish carriers of hereditary transthyretin amyloidosis
- Sex differences in hospitalizations among patients with transthyretin amyloid cardiomyopathy in the 6 months before diagnosis: Insights from the Nationwide Readmission Database
- Making information meaningful: Mapping the amyloidosis patient information journey in the UK
- Analysis of Hereditary Transthyretin Amyloidosis: Clinical Differentiation and Genetic Characterization of 5,000 Screened Cases in Germany, Austria, and Switzerland.
- Vagal Nerve Ultrasound in Swedish Patients with Hereditary V30M Transthyretin amyloidosis: A pilot study in Late-Onset cases
- idiopathic carpal tunnel syndrome as an early clinical indicator of transthyretin cardiac amyloidosis: findings from the CarPos study
- Transthyretin as a Biomarker in Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Insights into Disease Progression
- • Full title: Quality standards for the diagnosis and management of ATTR and AL amyloidosis: a nominal group technique study • Short title: Quality standards for ATTR and AL amyloidosis care
